Camptothecin/podophyllotoxin - Neovia

Drug Profile

Camptothecin/podophyllotoxin - Neovia

Alternative Names: Neo 801; NEV-801

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator Neovia Oncology
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor-1 alpha inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 25 Jan 2017 Camptothecin/podophyllotoxin - Neovia is available for licensing as of 25 Jan 2017. http://www.neoviaoncology.com/
  • 25 Jan 2017 Phase-I clinical trials in Cancer (Metastatic disease, Late-stage disease) in USA (IV) (NCT02797795)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top